Scholarlink

<p><b>Objectives.</b> To identify associations of polymorphic variants of the genes encoding the neurotrophic factors <i>BDNF</i>, <i>NGF</i>, and <i>NRG1</i> with the severity of affective disorders and anxiety levels over courses of treatment in patients with affective disorders (AD), as well as in patients with AD comorbid with Alcohol Use Disorder (AUD).<b>Materials and methods.</b> The study included 235 patients with AD and 62 with AD comorbid with AUD, aged 18– 65 years. The severity of AD was assessed using the depressive symptom rating scale (SIGH-SAD) and the clinical global impression scale (CGI), and anxiety levels were assessed using the HARS Hamilton Anxiety Rating Scale before and on day 28 of psychopharmacotherapy. Genotyping of polymorphic variants rs6265, rs7124442, rs11030104, and rs7103411 of the <i>BDNF</i> gene, rs6330 of the <i>NGF</i> gene, and rs3924999 of the <i>NRG1</i> gene was performed using the real-time polymerase chain reaction on a QuantStudio 5 amplifier (Applied Biosystems, USA) with TaqMan1 Validated SNP Genotyping Assay kits (Applied Biosystems, USA). <b>Results.</b> In AD, rs3924999*AA of the <i>NRG1</i> gene was found to be associated with lower disease severity as assessed by the SIGH-SAD scale for typical depressive symptoms before therapy; rs3924999*AG was associated with lower scores on the CGI scale on treatment day 28. In patients with AD comorbid with AUD, rs3924999*AG was associated with lower severity of AD on the SIGH-SAD scale on treatment day 28. Carriage of rs6330*AA of the <i>NGF</i> gene in patients with comorbidity of AD and AUD was associated with lower severity of anxiety symptoms on the HARS scale. <b>Conclusions.</b> Polymorphic variants of rs3924999 of the <i>NRG1</i> gene and rs6330 of the <i>NGF</i> gene were found to determine lower severity of depressive symptoms and lower levels of anxiety in patients with AD and AD comorbid with AUD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of Polymorphic Variants of Genes of Neurotrophic Factors on Disease Severity and Anxiety Levels in Patients with Affective Disorders and Comorbid Alcohol Use Disorder

  • 期刊论文

  • 发表日期：

    2026年8月3日

查看全文
  • N. M. Vyalova,
  • E. V. Mikhalitskaya,
  • O. V. Roshchina,
  • G. G. Simutkin,
  • S. N. Vasilyeva,
  • S. A. Ivanova

摘要

Objectives. To identify associations of polymorphic variants of the genes encoding the neurotrophic factors BDNF, NGF, and NRG1 with the severity of affective disorders and anxiety levels over courses of treatment in patients with affective disorders (AD), as well as in patients with AD comorbid with Alcohol Use Disorder (AUD).Materials and methods. The study included 235 patients with AD and 62 with AD comorbid with AUD, aged 18– 65 years. The severity of AD was assessed using the depressive symptom rating scale (SIGH-SAD) and the clinical global impression scale (CGI), and anxiety levels were assessed using the HARS Hamilton Anxiety Rating Scale before and on day 28 of psychopharmacotherapy. Genotyping of polymorphic variants rs6265, rs7124442, rs11030104, and rs7103411 of the BDNF gene, rs6330 of the NGF gene, and rs3924999 of the NRG1 gene was performed using the real-time polymerase chain reaction on a QuantStudio 5 amplifier (Applied Biosystems, USA) with TaqMan1 Validated SNP Genotyping Assay kits (Applied Biosystems, USA). Results. In AD, rs3924999*AA of the NRG1 gene was found to be associated with lower disease severity as assessed by the SIGH-SAD scale for typical depressive symptoms before therapy; rs3924999*AG was associated with lower scores on the CGI scale on treatment day 28. In patients with AD comorbid with AUD, rs3924999*AG was associated with lower severity of AD on the SIGH-SAD scale on treatment day 28. Carriage of rs6330*AA of the NGF gene in patients with comorbidity of AD and AUD was associated with lower severity of anxiety symptoms on the HARS scale. Conclusions. Polymorphic variants of rs3924999 of the NRG1 gene and rs6330 of the NGF gene were found to determine lower severity of depressive symptoms and lower levels of anxiety in patients with AD and AD comorbid with AUD.